Teva secures FDA approval for new formulation of COPAXONE

Israel-based Teva Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for its supplemental new drug application (sNDA) for three-times-a-week COPAXONE 40mg/mL, a new dose of COPAXONE (glatiramer acetate injection) ind…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news